Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 16 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 8349810

    Methods for targeted cleavage and recombination of CCR5

    Sangamo Biosciences, Inc. · Granted Jan 8, 2013 · Expires Jan 3, 2033

    granted

  2. US 8329753

    Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition

    The Regents of the University of Colorado · Granted Dec 11, 2012 · Expires Dec 6, 2032

    granted

  3. US 8268792

    Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases

    Reinhard Rettenberger · Granted Sep 18, 2012 · Expires Sep 13, 2032

    granted

  4. US 8258116

    Combination therapy for the treatment of HCV infection

    Vertex Pharmaceuticals Incorporated · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  5. US 8163542

    Potent combinations of mRNA transport elements

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Apr 24, 2012 · Expires Apr 19, 2032

    granted

  6. US 8158146

    Stable combinations of amlodipine besylate and benazepril hydrochloride

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 17, 2012 · Expires Apr 12, 2032

    granted

  7. US 8119649

    Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

    The Board of Regents of the University of Texas System · Granted Feb 21, 2012 · Expires Feb 16, 2032

    granted

  8. US 8048418

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  9. US 7977320

    Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents

    The Regents of the University of California · Granted Jul 12, 2011 · Expires Jul 7, 2031

    granted

  10. US 7972854

    Methods and compositions for targeted cleavage and recombination

    Sangamo Biosciences, Inc. · Granted Jul 5, 2011 · Expires Jun 30, 2031

    granted

  11. US 7968511

    Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 28, 2011 · Expires Jun 23, 2031

    granted

  12. US 7919484

    Combination therapy

    Xenon Pharmaceuticals Inc. · Granted Apr 5, 2011 · Expires Mar 31, 2031

    granted

  13. US 7902148

    Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent

    Theravance, Inc. · Granted Mar 8, 2011 · Expires Mar 3, 2031

    granted

  14. US 7888121

    Methods and compositions for targeted cleavage and recombination

    Sangamo Biosciences, Inc. · Granted Feb 15, 2011 · Expires Feb 10, 2031

    granted

  15. US 7858657

    Wortmannin analogs and methods of using same in combination with chemotherapeutic agents

    Arizona Board of Regents, Acting on Behalf of the University of Arizona · Granted Dec 28, 2010 · Expires Dec 23, 2030

    granted

  16. US 7795389

    Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins

    The Board of Regents of the University of Texas System · Granted Sep 14, 2010 · Expires Sep 9, 2030

    granted

  17. US 7795305

    CDDO-compounds and combination therapies thereof

    The Board of Regents of the University of Texas System · Granted Sep 14, 2010 · Expires Sep 9, 2030

    granted

  18. US 7790159

    Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Sep 7, 2010 · Expires Sep 2, 2030

    granted

  19. US 7790158

    Methods for epitope-specific and cytokine/anticytokine combination immunotherapies

    The Regents of the University of California · Granted Sep 7, 2010 · Expires Sep 2, 2030

    granted

  20. US 7714109

    Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

    The Board of Regents of the University of Texas System · Granted May 11, 2010 · Expires May 6, 2030

    granted

  21. US 7612093

    Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy

    United Therapeutics Corporation · Granted Nov 3, 2009 · Expires Oct 29, 2029

    granted

  22. US 7579333

    Therapy using a combination of raloxifene and alendronate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 25, 2009 · Expires Aug 20, 2029

    granted

  23. US 7521418

    Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent

    Theravance, Inc. · Granted Apr 21, 2009 · Expires Apr 16, 2029

    granted

  24. US 7459536

    HGF-SF monoclonal antibody combinations

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 2, 2008 · Expires Nov 27, 2028

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.